Oxaliplatin AqVida 100 mg per 20 ml

Oxaliplatin AqVida 100 mg Powder for Solution for Infusion

Oxaliplatin AqVida 100 mg is a crucial antineoplastic agent specifically formulated as a powder for solution for infusion. This medication is primarily utilized in the treatment of various types of cancer, often as part of a multi-drug chemotherapy regimen. It works by interfering with the DNA of cancer cells, thereby inhibiting their growth and proliferation. Developed to meet stringent pharmaceutical standards, Oxaliplatin AqVida is a cornerstone in modern oncology treatment plans, providing a targeted approach against malignant cells.

This product is designed for intravenous administration, ensuring precise delivery of the active substance directly into the bloodstream. Its formulation as a powder requires reconstitution before use, which is performed by qualified healthcare professionals under strict aseptic conditions. The 100 mg strength per vial is a standard dosage for clinical applications, allowing oncologists to tailor treatment protocols to individual patient needs and specific cancer types.

Benefits of Use:

Oxaliplatin AqVida offers significant benefits in the management of cancer:

• Effective against a range of solid tumors, including colorectal cancer, gastric cancer, and pancreatic cancer.
• Often used in combination therapies, enhancing the overall efficacy of chemotherapy protocols.
• Acts as a platinum-based alkylating agent, disrupting cancer cell DNA and preventing replication.
• Helps in improving disease-free survival and overall survival in eligible patients.

How to Use:

Oxaliplatin AqVida 100 mg is a prescription-only medication and must be administered by a healthcare professional trained in chemotherapy administration.

1. Oxaliplatin AqVida is supplied as a lyophilized powder in a vial and must be reconstituted with an appropriate solvent (e.g., Water for Injections or 5% Glucose solution) before administration.
2. The reconstituted solution is then diluted in 250 to 500 ml of 5% Glucose solution for intravenous infusion.
3. It is administered as an intravenous infusion over a period of 2 to 6 hours, usually every two to three weeks, as determined by the treating oncologist.
4. The exact dosage and frequency will depend on the patient's body surface area, renal function, type of cancer, and overall treatment regimen.
5. Strict adherence to aseptic techniques is paramount during preparation and administration to prevent contamination.

Caution & Warnings:

• Peripheral Neuropathy: A common side effect; patients should be monitored for sensory disturbances.
• Myelosuppression: May cause suppression of bone marrow, leading to anemia, leukopenia, and thrombocytopenia. Regular blood counts are essential.
• Hypersensitivity Reactions: Allergic reactions, including anaphylaxis, can occur, especially during or shortly after administration.
• Hepatotoxicity: Liver function should be monitored throughout treatment.
• Nephrotoxicity: Kidney function should be assessed before and during therapy.
• Pulmonary Toxicity: Rare but serious lung complications may occur.
• Gastrointestinal Effects: Nausea, vomiting, diarrhea, and mucositis are common.
• Pregnancy and Lactation: Contraindicated in pregnant or breastfeeding women due to potential harm to the fetus or infant.
• Extravasation: Care must be taken to avoid extravasation during infusion, which can cause severe local tissue damage.

Ingredients:

• Active Ingredient: Oxaliplatin 100 mg.
• Excipients: Specific excipients for lyophilized powder (e.g., lactose monohydrate, water for injections for reconstitution).

Product Details:

Product Name: Oxaliplatin AqVida 100 mg Powder for Solution for Infusion

Strength: 100 mg

Dosage Form: Lyophilized Powder for Solution for Infusion

Package Size: Single-dose vial

Manufacturer: AqVida GmbH

Legal Status: Prescription Only Medicine